CC
HAE icon

Centiva Capital’s Haemonetics HAE Stock Holding History

Centiva Capital’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,557
Closed -$377K – 2334
2024
Q2 		$377K Buy
+4,557
New +$401K 0.01% 1335
2023
Q3 		– Sell
-5,810
Closed -$495K – 1850
2023
Q2 		$495K Buy
+5,810
New +$491K 0.01% 836
2023
Q1 		– Sell
-4,581
Closed -$360K – 1646
2022
Q4 		$360K Sell
4,581
-2,008
-30% -$161K 0.01% 886
2022
Q3 		$488K Buy
+6,589
New +$473K 0.01% 887
2022
Q1 		– Sell
-8,080
Closed -$429K – 1703
2021
Q4 		$429K Buy
+8,080
New +$492K 0.01% 839
2021
Q3 		– Sell
-18,889
Closed -$1.26M – 1417
2021
Q2 		$1.26M Buy
18,889
+14,267
+309% +$1.01M 0.03% 475
2021
Q1 		$513K Buy
+4,622
New +$572K 0.02% 550

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

Centiva Capital's HAE Position: Q3 2024 in Review

Centiva Capital sold out of Haemonetics (HAE) in Q3 2024, closing a stake of 4,557 shares — an estimated $377K sold.

Centiva Capital first reported a position in HAE in Q1 2021 and held it in 7 quarters. The position peaked at $1.26M in Q2 2021. 306 funds tracked by Wall St. Rank hold HAE as of Q3 2024.

  • Centiva Capital reported no remaining Haemonetics position as of Q3 2024 after selling out during the quarter.
  • Centiva Capital sold 4,557 Haemonetics shares in Q3 2024, an estimated $377K.
  • Centiva Capital first reported a position in Haemonetics in Q1 2021 and held it in 7 quarters.
  • Centiva Capital's Haemonetics position peaked at $1.26M in Q2 2021.
  • 306 funds tracked by Wall St. Rank held Haemonetics as of Q3 2024.

Based on Centiva Capital's 13F filing for Q3 2024, filed 14 Nov 2024.